Publishing individual patient data from trials: EMA considering how and when
This article was originally published in SRA
Executive Summary
The European Medicines Agency's policy on proactive publication of clinical trial data, which currently pertains to clinical study reports from approved drugs, will eventually be expanded to allow access to individual patient data.
You may also be interested in...
EMA Reviews GSK/Vir’s COVID-19 Antibody To Support Early Use By Member States
After preliminary discussions with its pandemic task force, the European Medicines Agency has begun reviewing GSK/Vir Biotechnology’s promising COVID-19 treatment to help EU national competent authorities make evidence-based decisions on its possible early use.
Coronavirus Notebook: New EMA Review To Contextualize Blood Clot Risk From AZ Jab, EU Gets Earlier Access To More Pfizer Vaccines
Denmark has stopped using the AstraZeneca vaccine completely, while the Canadian regulator is not recommending restrictions in any specific populations. Can a new EMA review provide better context to guide the vaccine’s use in different age groups and gender?
EU Nitrosamines Oversight Group Identifies Priority Topics
After agreeing on an EU-wide harmonized approach to deal with nitrosamine contamination in medicines, a newly-created regulatory oversight group has identified several topics requiring further scientific discussion.